ArticleMolecular biotechnology2026
Structure-Guided Design and in Vivo Validation of a VP4-Derived Subunit Vaccine Candidate against Bovine Rotavirus.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Vaccine-Field Strain Gap in Bovine Neonatal Diarrhea: Molecular Epidemiology of Rotavirus, Coronavirus, and EnterotoxigenicVaccines · 2026Review
- Structure-Guided Design and in Vivo Validation of a VP4-Derived Subunit Vaccine Candidate against Bovine Rotavirus.Molecular biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A truncated VP4* fragment of Bovine Rotavirus was expressed in Escherichia coli, and optimal conditions for recombinant protein isolation and purification were established. Comprehensive bioinformatics-driven in silico and in vivo evaluation of the VP4* protein was carried out to assess its structural and immunological properties. In silico analysis of physicochemical properties revealed that VP4*fragments are antigenic, non-toxic, and non-allergenic. Structural validation showed that 99.3% of residues were within the favored region of the Ramachandran plot, confirming the reliability of the 3D model structure of the protein. The recombinant protein with bovine Toll-like Receptors (TLRs) was validated by molecular docking via ClusPro, showing strong binding affinities between the complexes. Molecular dynamics simulations (Desmond software) and computational immunology (C-ImmSim server) consistently indicated the constructs' structural integrity, stable receptor interaction, and capacity to elicit robust cellular and humoral immune responses. The in vivo immunogenicity results of VP4*antigen in Wistar rats were validated by the results obtained from computational immunological analysis. A comparative immune response study of the VP4* antigen with the rotavirus vaccine (ROTAVAC) or as a booster dose after vaccination was observed in Wistar rats. A high IgG level was shown in the group where the antigen was given as a booster dose after vaccination with no side effects in the rats, indicating that the protein is non-toxic, non-allergenic, potentially immunogenic, and represents a promising candidate for further evaluation in rotavirus prevention.
Indexed as
Identifiers
41326945What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.